Alterity Therapeutics Limited (ATHE) Cash Flow Statement
Where ATHE’s cash came from and went, FY2026
June 30, 2026 · Australian dollars- Cash from operations
- −A$22.0M
- Capital expenditures
- A$22.0M
- Free cash flow
- −A$22.5M
- Returned to shareholders
- —
- Change in cash
- A$6.0M cash at year-end A$37.3M
Cash from operations
−A$22.0M
Capital expenditures
−A$22.0M
Investments (net)
+A$7.5M
Acquisitions & other
+A$21.9M
Net borrowing (repayment)
−A$136,559
Shares issued
+A$20.4M
Other financing
−A$1.5M
Currency & other
+A$1.9M
Change in cash
A$6.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ATHE operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
ATHE cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −A$5.9MFY2017 | −A$22.0MFY2026 | — | |
| Capital expenditures | A$27,918FY2017 | A$22.0MFY2026 | +109.8%/yr | |
| Free cash flow | −A$5.9MFY2017 | −A$22.5MFY2026 | — | |
| Free cash flow margin | −4,451.0%FY2017 | −210.5%FY2025 | +4,240.5 pts | |
| Stock-based compensation | A$24,460FY2017 | A$979,920FY2025 | +58.6%/yr | |
| Dividends paid | A$0FY2017 | A$0FY2023 | — | |
| Share buybacks (net) | A$0FY2017 | A$0FY2019 | — | |
| Capex / revenue | 21.1%FY2017 | 0.0%FY2025 | −21.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ATHE cash flow by activity
OperatingInvestingFinancingChange in cash
ATHE net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ATHE cash flow statement in Australian dollars
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −A$22.9M | −A$12.1M | −A$19.1M | −A$13.8M | −A$12.8M | −A$15.3M | −A$10.1M | −A$12.3M | −A$8.3M | −A$7.5M |
| Depreciation & amortization | A$113,010 | A$139,715 | A$147,529 | A$102,263 | A$54,214 | A$75,369 | A$112,427 | A$29,696 | A$21,799 | A$21,328 |
| Stock-based compensation | — | A$979,920 | A$881,950 | A$966,571 | A$1.5M | A$1.9M | −A$12,016 | A$89,138 | A$764,539 | A$24,460 |
| Change in working capital | −A$3.6M | −A$613,678 | A$5.7M | −A$3.9M | −A$447,684 | −A$4.2M | A$791,128 | −A$1.3M | A$956,094 | A$975,189 |
| Other non-cash items | A$4.4M | A$190,623 | −A$261,152 | −A$3.4M | −A$602,865 | A$235,508 | −A$262,977 | −A$403,879 | A$278,117 | A$656,019 |
| Cash from operating activities | −A$22.0M | −A$11.5M | −A$12.6M | −A$20.0M | −A$12.3M | −A$17.3M | −A$9.4M | −A$14.0M | −A$6.2M | −A$5.9M |
| Investing activities | ||||||||||
| Capital expenditures | −A$22.0M | −A$3 | −A$5,722 | −A$7,311 | −A$89,147 | −A$10,472 | −A$16,744 | −A$7,022 | −A$62,405 | −A$27,918 |
| Investments (net) | A$7.5M | −A$7.5M | −A$5,722 | −A$5,000 | −A$89,000 | −A$3,000 | −A$16,744 | −A$7,022 | −A$18,417 | −A$27,918 |
| Acquisitions & other investing | A$21.9M | A$3 | A$5,722 | −A$24,150 | A$89,000 | A$3,000 | A$16,744 | A$7,022 | A$62,405 | A$27,918 |
| Cash from investing activities | A$7.3M | −A$7.5M | −A$5,722 | −A$36,461 | −A$89,147 | −A$10,472 | −A$16,744 | −A$7,022 | −A$18,417 | −A$27,918 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | A$13.1M | A$0 | A$0 |
| Net borrowing (repayment) | −A$136,559 | −A$127,097 | −A$10,370 | −A$59,922 | −A$34,513 | −A$58,289 | −A$89,241 | −A$89,241 | −A$89,241 | −A$89,241 |
| Shares issued | A$20.4M | A$42.6M | A$10.1M | A$311,000 | A$17.2M | A$39.2M | A$4.4M | A$13.1M | A$0 | A$0 |
| Other financing | −A$1.5M | −A$2.8M | −A$918,020 | −A$126,738 | −A$836,929 | −A$2.5M | −A$292,768 | −A$13.4M | −A$18,437 | −A$70,323 |
| Cash from financing activities | A$18.7M | A$39.7M | A$9.2M | A$124,340 | A$16.3M | A$36.7M | A$4.0M | A$12.7M | −A$107,678 | −A$159,564 |
| Summary | ||||||||||
| Net change in cash | A$6.0M | A$20.5M | −A$3.1M | −A$19.0M | A$6.7M | A$18.9M | −A$5.2M | −A$835,652 | −A$6.6M | −A$6.7M |
| Cash at end of period | A$37.3M | A$33.2M | A$12.6M | A$15.8M | A$34.8M | A$28.1M | A$9.2M | A$14.4M | A$15.2M | A$21.9M |
| Free cash flow | −A$22.5M | −A$11.5M | −A$12.6M | −A$20.0M | −A$12.4M | −A$17.3M | −A$9.4M | −A$14.0M | −A$6.3M | −A$5.9M |
| Free cash flow margin | — | −210.5% | −313.8% | −511.8% | −242.5% | −399.6% | −2,295.6% | −12,863.6% | −3,135.4% | −4,451.0% |
| Capex / revenue | — | 0.0% | 0.1% | 0.2% | 1.7% | 0.2% | 4.1% | 6.5% | 31.0% | 21.1% |
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||
| Net income | −A$14.0M | −A$9.4M | −A$3.2M | −A$7.2M | −A$3.6M | −A$12.6M | −A$4.2M | — | −A$3.9M |
| Depreciation & amortization | A$58,457 | A$56,828 | A$71,117 | A$70,667 | A$36,295 | A$73,612 | A$75,343 | — | A$52,565 |
| Stock-based compensation | — | — | −A$141,341 | A$1.1M | A$560,631 | A$569,663 | A$312,287 | — | A$322,198 |
| Change in working capital | −A$604,539 | −A$3.3M | A$3.4M | −A$2.0M | −A$1.0M | A$3.1M | A$1.6M | — | −A$2.9M |
| Other non-cash items | A$1.7M | A$2.2M | −A$2.6M | −A$368,717 | −A$185,320 | A$723,929 | −A$2.3M | — | −A$3.7M |
| Cash from operating activities | −A$12.8M | −A$10.4M | −A$2.4M | −A$8.4M | −A$4.2M | −A$8.1M | −A$4.5M | A$549,000 | −A$10.1M |
| Investing activities | |||||||||
| Capital expenditures | −A$12.8M | −A$10.4M | A$0 | −A$2 | A$0 | −A$278 | −A$2,000 | −A$4,000 | −A$2,434 |
| Investments (net) | A$7.5M | A$7.5M | −A$7.5M | A$0 | A$0 | −A$722 | −A$1,000 | −A$4,000 | −A$26,584 |
| Acquisitions & other investing | A$5.8M | A$10.3M | A$0 | — | — | A$278 | A$2,000 | A$4,000 | A$2,434 |
| Cash from investing activities | A$511,794 | A$7.4M | −A$7.5M | — | — | −A$722 | −A$1,000 | −A$4,000 | −A$26,584 |
| Financing activities | |||||||||
| Dividends paid | — | A$0 | — | A$0 | A$0 | — | A$0 | A$0 | A$0 |
| Net borrowing (repayment) | −A$136,559 | −A$33,247 | −A$127,097 | −A$68,249 | A$0 | −A$10,370 | — | — | −A$16,077 |
| Shares issued | A$0 | A$20.4M | A$27.2M | A$398,645 | A$0 | A$94,682 | A$1.1M | A$0 | A$5,833 |
| Other financing | A$1.4M | −A$1.5M | −A$1.8M | A$38,923 | A$149,160 | A$8.1M | −A$156,000 | −A$17,000 | −A$2,518 |
| Cash from financing activities | A$1.2M | A$18.8M | A$25.2M | A$369,319 | A$149,160 | A$8.2M | A$970,000 | −A$17,000 | −A$12,762 |
| Summary | |||||||||
| Net change in cash | −A$10.0M | A$16.6M | A$15.2M | −A$4.7M | — | A$318,459 | −A$4.4M | A$936,000 | −A$25.3M |
| Cash at end of period | A$37.3M | A$49.2M | A$33.2M | A$4.5M | A$9.3M | A$12.6M | A$12.3M | A$16.7M | A$15.8M |
| Free cash flow | −A$7.2M | −A$5.3M | −A$2.4M | −A$8.4M | −A$4.2M | −A$8.1M | −A$4.9M | A$545,000 | −A$6.2M |
| Free cash flow margin | — | — | −61.4% | −520.5% | −520.5% | −382.8% | −255.9% | 57.3% | −405.4% |
| Capex / revenue | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.4% | 0.2% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported; data from EODHD.
ATHE cash generation
In fiscal 2026 (ended June 30, 2026), Alterity Therapeutics generated -A$22.0 million of cash from operations and spent A$22.0 million on capital expenditures, leaving free cash flow of -A$22.5 million. Cash and equivalents rose by A$6.0 million over the year.
Related: ATHE income statement, ATHE balance sheet. See the ATHE stock overview for the latest quote and news.
ATHE cash flow FAQ
What is Alterity Therapeutics's free cash flow?
Alterity Therapeutics's free cash flow was -A$22.5 million in fiscal 2026: -A$22.0 million of operating cash flow minus A$22.0 million of capital expenditures It was -A$11.5 million a year earlier..
How much cash does Alterity Therapeutics generate from operations?
Alterity Therapeutics generated -A$22.0 million of cash from operating activities in fiscal 2026.
How much does Alterity Therapeutics spend on capital expenditures?
Alterity Therapeutics spent A$22.0 million on capital expenditures in fiscal 2026, compared with A$0.0 million the year before.